UPDATE: GSK Q2 Adj. EPS $0.97 Beats $0.87 Estimate, Sales $8.97B Beat $8.97B Estimate
Portfolio Pulse from Benzinga Newsdesk
GSK reported Q2 earnings of $0.97 per share, beating the analyst consensus estimate of $0.87 by 11.49%. The company also reported quarterly sales of $8.97 billion, beating the analyst consensus estimate by 0.03%. This represents a 2.95% increase over sales from the same period last year.
July 26, 2023 | 9:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK's Q2 earnings and sales beat analyst estimates, which could lead to a positive short-term impact on the stock.
GSK's better-than-expected Q2 earnings and sales figures are likely to boost investor confidence and could lead to a short-term increase in the stock price. The 11.49% increase in earnings and 2.95% increase in sales YoY indicate strong performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100